Compare Stocks: ENVB, VIRI, PLRZ, and BGM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$9.34 +19.4%	$8.25	$6.45 ▼ $317.10	$908.04M	1.85	9,533 shs	38,470 shs
ENVB Enveric Biosciences	$1.48 +1.4%	$1.47	$1.17 ▼ $13.25	$6.63M	1.18	1.44 million shs	72,491 shs
PLRZ Polyrizon	$9.61 -6.9%	$11.33	$2.88 ▼ $18.20	$23.35M	-1.19	63,449 shs	56,467 shs
VIRI Virios Therapeutics	$1.43 +5.9%	$1.93	$0.13 ▼ $1.04	$27.54M	1.58	1.05 million shs	26,517 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	+3.52%	+4.81%	-4.48%	-19.55%	-97.50%
ENVB Enveric Biosciences	-2.54%	-5.50%	+6.57%	+0.69%	-81.62%
PLRZ Polyrizon	+1.27%	+1.22%	-25.92%	-22.91%	+62.66%
VIRI Virios Therapeutics	0.00%	-10.60%	-47.67%	-9.40%	-82.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$9.34 +19.4%	$8.25	$6.45 ▼ $317.10	$908.04M	1.85	9,533 shs	38,470 shs
ENVB Enveric Biosciences	$1.48 +1.4%	$1.47	$1.17 ▼ $13.25	$6.63M	1.18	1.44 million shs	72,491 shs
PLRZ Polyrizon	$9.61 -6.9%	$11.33	$2.88 ▼ $18.20	$23.35M	-1.19	63,449 shs	56,467 shs
VIRI Virios Therapeutics	$1.43 +5.9%	$1.93	$0.13 ▼ $1.04	$27.54M	1.58	1.05 million shs	26,517 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	+3.52%	+4.81%	-4.48%	-19.55%	-97.50%
ENVB Enveric Biosciences	-2.54%	-5.50%	+6.57%	+0.69%	-81.62%
PLRZ Polyrizon	+1.27%	+1.22%	-25.92%	-22.91%	+62.66%
VIRI Virios Therapeutics	0.00%	-10.60%	-47.67%	-9.40%	-82.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM BGM Group	1.00	Sell	N/A	N/A
ENVB Enveric Biosciences	1.00	Sell	N/A	N/A
PLRZ Polyrizon	1.00	Sell	N/A	N/A
VIRI Virios Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ENVB, VIRI, PLRZ, and BGM Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/18/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/6/2026	BGM BGM Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
7/29/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	ENVB Enveric Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM BGM Group	$37.92M	23.65	N/A	N/A	$4.03 per share	2.29
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	$7.00 per share	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	$13.05 per share	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM BGM Group	-$19.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENVB Enveric Biosciences	-$8.77M	-$12.65	N/A	N/A	N/A	N/A	-168.04%	-145.95%	11/12/2026 (Estimated)
PLRZ Polyrizon	-$3.34M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	N/A

Latest ENVB, VIRI, PLRZ, and BGM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/28/2026	Q2 2026	PLRZ Polyrizon	N/A	-$0.3950	N/A	-$0.3950	N/A	N/A
8/28/2026	Q2 2026	BGM BGM Group	N/A	-$0.30	N/A	-$0.0050	N/A	$12.15 million
8/14/2026	Q2 2026	ENVB Enveric Biosciences	N/A	-$0.76	N/A	-$0.76	N/A	N/A
7/21/2026	Q4 2025	BGM BGM Group	N/A	-$80.70	N/A	-$2.6850	N/A	$11.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM BGM Group	N/A	1.25	0.73
ENVB Enveric Biosciences	N/A	10.21	10.21
PLRZ Polyrizon	N/A	36.37	N/A
VIRI Virios Therapeutics	N/A	7.27	7.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM BGM Group	N/A
ENVB Enveric Biosciences	13.82%
PLRZ Polyrizon	N/A
VIRI Virios Therapeutics	9.05%

Insider Ownership

Company	Insider Ownership
BGM BGM Group	58.66%
ENVB Enveric Biosciences	2.41%
PLRZ Polyrizon	N/A
VIRI Virios Therapeutics	12.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM BGM Group	471	97.22 million	40.19 million	N/A
ENVB Enveric Biosciences	6	4.48 million	4.37 million	Not Optionable
PLRZ Polyrizon	1	2.43 million	N/A	N/A
VIRI Virios Therapeutics	5	19.26 million	16.91 million	No Data

ENVB, VIRI, PLRZ, and BGM Headlines

Recent News About These Companies

Virios Therapeutics (NASDAQ:VIRI) Trading Down 1.7% - Here's Why

September 22, 2026 | americanbankingnews.com

Die Virios-Therapeutics-Aktie bleibt ein spekulativer Nebenwert im Biotech-Segment

September 5, 2026 | ad-hoc-news.deA

Digital acceptance and commitment therapy for fibromyalgia – Authors' reply

June 13, 2025 | thelancet.comT

Dogwood Therapeutics Inc (DWTX)

March 16, 2025 | investing.com

Dogwood prices 578,950 shares at $8.26 in registered direct offering

March 13, 2025 | markets.businessinsider.com

Dogwood announces conversion of existing $19.5M in debt to equity

March 12, 2025 | markets.businessinsider.com

DWTX Stock trading resumes

February 11, 2025 | markets.businessinsider.com

Dogwood Therapeutics, Inc. (DWTX)

February 2, 2025 | finance.yahoo.com

DWTX Stock trading halted, volatility trading pause

January 28, 2025 | markets.businessinsider.com

DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth

January 23, 2025 | msn.com

Dogwood announces first patient dosed in Phase 2b trial on Halneuron

January 21, 2025 | markets.businessinsider.com

Polluted communities hold their breath as companies struggle with California’s diesel truck ban

December 10, 2024 | apnews.comA

Dogwood Therapeutics faces potential Nasdaq delisting

November 23, 2024 | uk.investing.com

Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue

November 18, 2024 | markets.businessinsider.com

Dogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep Disturbance

November 18, 2024 | markets.businessinsider.com

Inovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News Summary

November 16, 2024 | benzinga.com

DWTX: Phase 2 Long COVID Results Expected Soon

November 12, 2024 | msn.com

Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence

November 10, 2024 | markets.businessinsider.com

Dogwood Therapeutics Reports Q3 2024 Financial Results

November 9, 2024 | markets.businessinsider.com

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

November 8, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB, VIRI, PLRZ, and BGM Company Descriptions

BGM Group NASDAQ:BGM

$9.34 +1.52 (+19.44%)

Closing price 03:58 PM Eastern

Extended Trading

$9.27 -0.07 (-0.75%)

As of 05:51 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Enveric Biosciences NASDAQ:ENVB

$1.48 +0.02 (+1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$1.47 -0.01 (-0.61%)

As of 05:56 PM Eastern

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Polyrizon NASDAQ:PLRZ

$9.61 -0.71 (-6.88%)

Closing price 03:56 PM Eastern

Extended Trading

$9.71 +0.10 (+1.05%)

As of 05:31 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

Virios Therapeutics NASDAQ:VIRI

$1.43 +0.08 (+5.93%)

As of 10/1/2026

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENVB, VIRI, PLRZ, and BGM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENVB, VIRI, PLRZ, and BGM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENVB, VIRI, PLRZ, and BGM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB, VIRI, PLRZ, and BGM Company Descriptions

BGM Group NASDAQ:BGM

Enveric Biosciences NASDAQ:ENVB

Polyrizon NASDAQ:PLRZ

Virios Therapeutics NASDAQ:VIRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENVB, VIRI, PLRZ, and BGM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENVB, VIRI, PLRZ, and BGM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENVB, VIRI, PLRZ, and BGM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB, VIRI, PLRZ, and BGM Company Descriptions

BGM Group NASDAQ:BGM

Enveric Biosciences NASDAQ:ENVB

Polyrizon NASDAQ:PLRZ

Virios Therapeutics NASDAQ:VIRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools